Evidence map›Paper›PMID 19713997›Full record

ArticleCancer gene therapy2010

An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth.

T Liu, A K Chopra

Open access · greenAbstract read
In one paragraph

Article in Cancer gene therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Deficiency in theMicroorganisms · 2025
    Article
  3. Converting bacteria into autologous tumor vaccineActa pharmaceutica Sinica. B · 2023
    Article
  4. Review
  5. Frontiers in cellular and infection microbiology · 2023
    Review
  6. Review
  7. Pharmaceutics · 2022
    Review
  8. Recombinant AttenuatedCancers · 2022
    Review
  9. Integration ofCancers · 2021
    Review
  10. OralFrontiers in immunology · 2021
    Article
  11. Perspectives on OncolyticFrontiers in immunology · 2021
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

T LiuDepartment of Microbiology and Immunology, Center for Biodefense & Emerging Infectious Diseases and Sealy Center for Vaccine Development, Institute of Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555-1070, USA.
A K Chopra
The University of Texas Medical Branch at Galveston · US

Funding

Identification of New Antigens for a Plague VaccineR01AI064389 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI CHOPRA, ASHOK K · 2005 to 2015
$3.8M
NIAID NIH HHS AI064389NIAID NIH HHS R01 AI064389
6 · The paper itself

Abstract

An antitumor activity associated with several bacterial pathogens, including Salmonella enterica serovar Typhimurium, has been reported; however, the underlying immunological mechanism(s) that lead to an antitumor effect are currently unclear. Furthermore, such pathogens cannot be used to suppress tumor growth because of their potential for causing sepsis. Recently, we reported the characterization of S. Typhimurium isogenic mutants from which Braun lipoprotein genes (lppA and B) and the multicopy repressor of high temperature requirement (msbB) gene were deleted. In a mouse infection model, two mutants, namely, lppB/msbB and lppAB/msbB, minimally induced proinflammatory cytokine production at high doses and were nonlethal to animals. We showed that immunization of mice with these mutants, followed by challenge with the wild-type S. Typhimurium, could significantly suppress tumor growth, as evidenced by an 88% regression in tumor size in lppB/msbB mutant-immunized animals over a 24-day period. However, the lppAB/msbB mutant alone was not effective in modulating tumor growth in mice, although the lppB/msbB mutant alone caused marginal regression in tumor size. Importantly, we showed that CD44(+) cells grew much faster than CD44(-) cells from human liver tumors in mice, leading us to examine the possibility that S. Typhimurium might downregulate CD44 in tumors and splenocytes of mice. Consequently, we found in S. Typhimurium-infected mice that tumor size regression could indeed be related to the downregulation of CD44(high) and CD4(+)CD25(+) T(reg) cells. Importantly, the role of lipopolysaccharide and Braun lipoprotein was critical in S. Typhimurium-induced antitumor immune responses. Taken together, we have defined new immune mechanisms leading to tumor suppression in mice by S. Typhimurium.

Indexed as

AnimalsBacterial ProteinsCell Line, TumorFemaleFlow CytometryHumansHyaluronan ReceptorsInterleukin-2 Receptor alpha SubunitLipopolysaccharidesLipoproteinsMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasmsSalmonella typhimuriumT-Lymphocytes, RegulatoryBacterial ProteinsCD44S antigenHyaluronan ReceptorsInterleukin-2 Receptor alpha SubunitLipopolysaccharidesLipoproteins

Identifiers

PMID19713997
PMCPMC2808459
OpenAlexW2062009351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.